Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A safety and tolerability study in healthy subjects including examination of how the body takes up, distributes, and gets rid of ACT-1014-6470
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ACT-1014-6470 single dose (dose level 1) | Experimental | Soft capsule for oral administration |
|
| Placebo single dose (dose level 1) | Placebo Comparator | Soft capsule for oral administration |
|
| ACT-1014-6470 single dose (dose level 2) | Experimental | Soft capsule for oral administration |
|
| Placebo single dose (dose level 2) | Placebo Comparator | Soft capsule for oral administration |
|
| ACT-1014-6470 multiple dose (dose level 1) | Experimental | Soft capsule for oral administration |
|
| Placebo multiple dose (dose level 1) | Placebo Comparator | Soft capsule for oral administration |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACT-1014-6470 | Drug | Soft capsules for oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety profile including incidence of treatment-emergent adverse events. | Safety and tolerability assessments will be performed at predefined time points from Day 1 to Day 4 in Part A and Day 1 to Day 10 in Part B (total duration: max. 50 days). |
| Measure | Description | Time Frame |
|---|---|---|
| Part A - Single ascending dose (SAD): Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t). | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days). | |
| Part A - Single ascending dose (SAD): Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf). |
Not provided
Inclusion Criteria:
General criteria
Criteria for Part B only:
• Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day-1.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Parexel International GmbH Klinikum Westend | Berlin | 14050 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Single-center, double-blind, randomized, placebo-controlled, single- and multiple-ascending dose
Not provided
Not provided
Not provided
|
| ACT-1014-6470 multiple dose (dose level 2) | Experimental | Soft capsule for oral administration |
|
| Placebo multiple dose (dose level 2) | Placebo Comparator | Soft capsule for oral administration |
|
| ACT-1014-6470 multiple dose (dose level 3) | Experimental | Soft capsule for oral administration |
|
| Placebo multiple dose (dose level 3) | Placebo Comparator | Soft capsule for oral administration |
|
| ACT-1014-6470 multiple dose (dose level 4) | Experimental | Soft capsule for oral administration |
|
| Placebo multiple dose (dose level 4) | Placebo Comparator | Soft capsule for oral administration |
|
| Placebo | Drug | Soft capsules for oral administration |
|
| Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days). |
| Part A - Single ascending dose (SAD): Maximum plasma concentration (Cmax). | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days). |
| Part A - Single ascending dose (SAD): Time to reach Cmax (tmax). | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days). |
| Part A - Single ascending dose (SAD): Terminal half-life (t½). | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 4 (total duration: max. 4 days). |
| Part B - Multiple ascending dose (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose. | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days). |
| Part B - Multiple ascending dose (MAD): Cmax of the first and the last dosing interval. | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days). |
| Part B - Multiple ascending dose (MAD): tmax of the first and the last dosing interval. | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days). |
| Part B - Multiple ascending dose (MAD): t½ after last dose administration. | Blood samples for the determination of the PK parameters will be collected at predefined time points from Day 1 to Day 10 (total duration: max. 10 days). |
| ID | Term |
|---|---|
| C000726455 | ACT-1014-6470 |
Not provided
Not provided
Not provided